Compare Fubotv Inc (FUBO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Neurocrine Biosciences Inc — how do they compare? Fubotv Inc trades at $8.84 (market cap $1.02B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 14.1× Fubotv Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FUBO | NBIX | |
|---|---|---|
Market Cap | $1.02B | $14.36B |
Volume | 978,631 | 1,237,180 |
Sector | Media | Health |
52-Week High | $48.96 | $185.50 |
52-Week Low | $8.09 | $123.10 |
Typical Hold Time | 35 Days | 23 Days |
Enterprise Value | $1.19B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.35, up 1.08% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported revenue of $1.62 billion in 2024, with a net loss of $172.25 million, though the net income margin improved to -10.62%. Recent news highlights strategic partnerships with the NHL and The Athletic to expand sports content offerings. Analyst consensus is a Buy with a $63.38 price target, but cash flow remains negative, and the stock is heavily shorted.
The outlook for FUBO hinges on its ability to achieve profitability through subscriber growth and cost management. Opportunities include leveraging Disney's operational expertise and new sports distribution deals. Key risks are persistent cash burn, high debt levels, and intense competition in the streaming sector. The stock presents a speculative opportunity with significant upside if turnaround efforts succeed, but investors should be cautious of execution risks and market volatility.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with technical indicators showing a bearish trend despite strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.85 significantly exceeding expectations of $1.85. Revenue growth remains strong, projected to increase from $2.9B in 2025 to $3.4B in 2026, while net profit margins expanded from 16.73% to 20.91%.
Wall Street maintains strong bullish sentiment with 86% buy ratings and a $204.18 consensus price target, representing 45% upside potential. Key risks include execution challenges with the expanding product portfolio and potential pricing pressure on INGREZZA ahead of 2029 patent considerations. The technical bearish signal contrasts with fundamental strength, creating potential entry opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
